LUGANO, Switzerland • February 28th, 2025 • Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibody-drug conjugates (ADCs).
The inauguration was conducted in the presence of Christian Suà, CEO of Cerbios-Pharma, and the members of Cerbios team whose expertise and commitment made this expansion possible. The manufacturing unit is equipped with isolator containment technology for highly potent molecules down to an OEL <10 ng/m3. This advanced facility ensures maximum flexibility to accommodate a wide range of molecule types.
With the investment, Cerbios offers expanded capacity for state-of-the-art purification technologies such as high and low pressure chromatography, nanofiltration and freeze-drying. The new area is located within the latest constructed facility which was approved by Swissmedic in 2023, providing an immediate additional capacity to serve the increasing market demand for this product category.
This milestone reinforces Cerbios-Pharma’s strategic investment in high-potency manufacturing and strengthens its position as a leading CMO in the commercial supply of HPAPIs and ADCs.
